SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 123 filers reported holding SYNDAX PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.11 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $174,000 | +79.4% | 10,000 | -23.1% | 0.28% | -1.8% |
Q3 2019 | $97,000 | -26.0% | 13,000 | -48.0% | 0.28% | +317.9% |
Q1 2019 | $131,000 | -41.0% | 25,000 | -50.0% | 0.07% | -52.8% |
Q4 2018 | $222,000 | +19.4% | 50,000 | +116.9% | 0.14% | +69.0% |
Q3 2018 | $186,000 | -45.9% | 23,053 | -53.0% | 0.08% | -35.9% |
Q2 2018 | $344,000 | – | 49,000 | – | 0.13% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |